 REDWOOD CITY, CA ACCESSWIRE July 9, 2020 Avinger, Inc. AVGR, a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease PAD, today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 3,000,000 shares of its common stock at a price of 0.27 per share. The shares were offered pursuant to a registration statement on Form S-1 File No. 333-239177 previously filed with the Securities and Exchange Commission SEC, and a related registration statement on Form S-1 File No. 333-239398 filed pursuant to rule 462b of the Securities Act of 1933, which registration statements were declared effective by the SEC. 